Molecular CYP21A2 diagnosis in 480 Brazilian patients with congenital adrenal hyperplasia before newborn screening introduction
Open Access
- 1 August 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 175 (2), 107-116
- https://doi.org/10.1530/eje-16-0171
Abstract
Background Most congenital adrenal hyperplasia (CAH) patients carry CYP21A2 mutations derived from conversion events involving the pseudogene, and the remaining carry new mutations. Objective To review causal mutations and genotype–phenotype correlation in 480 Brazilian patients. Methods DNA was extracted from 158 salt-wasters (SWs), 116 simple virilizing (SV), and 206 nonclassical (NC) patients. Fourteen point mutations were screened by allele-specific PCR, large rearrangements by Southern blotting/MLPA, and sequencing was performed in those with incomplete genotype. The gene founder effect was analyzed by microsatellite studies. Patients were divided into six genotypes (Null; A: 20% of residual enzymatic activity (EA); D: unknown EA; E: incomplete genotype). Results Targeted methodologies defined genotype in 87.6% of classical and in 80% of NC patients and the addition of sequencing in 100 and 83.5%, respectively. The most frequent mutations were p.V281L (26.6% of alleles), IVS2-13A/C>G (21.1%), and p.I172N (7.5%); seven rare mutations and one novel mutation (p.E351V) were identified. Gene founder effect was observed in all but one (p.W19X) mutation. Null, A, B, and C genotypes correlated with SW (88%), SW (70%), SV (98%), and NC forms (100%), respectively. In group D, the p.E351V mutation correlated with classical form and group E comprised exclusively NC-patients. ACTH-stimulated 17OHP level of 44.3ng/mL was the best cutoff to identify NC-patients carrying severe mutations. Conclusions We identified a good genotype–phenotype correlation in CAH, providing useful data regarding prediction of disease’s severity; moreover, we suggest that ACTH-stimulated 17OHP levels could predict carrier status for severe mutations. Sequencing is essential to optimize molecular diagnosis in Brazilian CAH patients. Abstract Background Most congenital adrenal hyperplasia (CAH) patients carry CYP21A2 mutations derived from conversion events involving the pseudogene, and the remaining carry new mutations. Objective To review causal mutations and genotype–phenotype correlation in 480 Brazilian patients. Methods DNA was extracted from 158 salt-wasters (SWs), 116 simple virilizing (SV), and 206 nonclassical (NC) patients. Fourteen point mutations were screened by allele-specific PCR, large rearrangements by Southern blotting/MLPA, and sequencing was performed in those with incomplete genotype. The gene founder effect was analyzed by microsatellite studies. Patients were divided into six genotypes (Null; A: 20% of residual enzymatic activity (EA); D: unknown EA; E: incomplete genotype). Results Targeted methodologies defined genotype in 87.6% of classical and in 80% of NC patients and the addition of sequencing in 100 and 83.5%, respectively. The most frequent mutations were p.V281L (26.6% of alleles), IVS2-13A/C>G (21.1%), and p.I172N (7.5%); seven rare mutations and one novel mutation (p.E351V) were identified. Gene founder effect was observed in all but one (p.W19X) mutation. Null, A, B, and C genotypes correlated with SW (88%), SW (70%), SV (98%), and NC forms (100%), respectively. In group D, the p.E351V mutation correlated with classical form and group E comprised exclusively NC-patients. ACTH-stimulated 17OHP level of 44.3ng/mL was the best cutoff to identify NC-patients carrying severe mutations. Conclusions We identified a good genotype–phenotype correlation in CAH, providing useful data regarding prediction of disease’s severity; moreover, we suggest that ACTH-stimulated 17OHP levels could predict carrier status for severe mutations. Sequencing is essential to optimize molecular diagnosis in Brazilian CAH patients.This publication has 43 references indexed in Scilit:
- Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency: From Birth to AdulthoodSeminars in Reproductive Medicine, 2012
- Weight-adjusted neonatal 17OH-progesterone cutoff levels improve the efficiency of newborn screening for congenital adrenal hyperplasiaArchives of Endocrinology and Metabolism, 2011
- Steroid 21‐hydroxylase gene mutational spectrum in 454 Argentinean patients: genotype–phenotype correlation in a large cohort of patients with congenital adrenal hyperplasiaClinical Endocrinology, 2011
- The Actual Incidence of Congenital Adrenal Hyperplasia in Brazil May Not be as High as Inferred - An Estimate Based on a Public Neonatal Screening Program in the State of GoiásJournal of Pediatric Endocrinology and Metabolism, 2008
- Nonclassical 21-Hydroxylase DeficiencyJournal of Clinical Endocrinology & Metabolism, 2006
- Estudo multicêntrico de pacientes brasileiros com deficiência da 21-hidroxilase: correlação do genótipo com o fenótipoArchives of Endocrinology and Metabolism, 2004
- A Multicenter Study of Women with Nonclassical Congenital Adrenal Hyperplasia: Relationship between Genotype and PhenotypeMolecular Genetics and Metabolism, 2000
- Predicting Phenotype in Steroid 21-Hydroxylase Deficiency? Comprehensive Genotyping in 155 Unrelated, Well Defined Patients from Southern GermanyJournal of Clinical Endocrinology & Metabolism, 2000
- Molecular Genotyping in Brazilian Patients with the Classical and Nonclassical Forms of 21-Hydroxylase DeficiencyJournal of Clinical Endocrinology & Metabolism, 1998
- Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestationJournal of Clinical Endocrinology & Metabolism, 1994